Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1902 | Immunoglobulin Wiki | 0.71 |
| drug2744 | Oxygen supply Wiki | 0.71 |
| drug3382 | Ritonavir/lopinavir Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4033 | Tocilizumab Injection [Actemra] Wiki | 0.71 |
| drug3850 | Synthetic neutralising antibodies Wiki | 0.71 |
| drug2208 | Low-dose radiotherapy Wiki | 0.71 |
| drug2846 | Peginterferon Lambda-1A Wiki | 0.50 |
| drug2200 | Low molecular weight heparin Wiki | 0.50 |
| drug2165 | Lopinavir-Ritonavir Wiki | 0.50 |
| drug421 | Azithromycin Wiki | 0.23 |
| drug1795 | Hydroxychloroquine Sulfate Wiki | 0.20 |
| drug4650 | placebo Wiki | 0.18 |
| drug1060 | Convalescent plasma Wiki | 0.15 |
| drug4025 | Tocilizumab Wiki | 0.12 |
| drug1775 | Hydroxychloroquine Wiki | 0.07 |
Navigate: Correlations HPO
There are 2 clinical trials
Low radiation doses produce anti-inflammatory effects, which may be useful in the treatment of respiratory complications of COVID-19. This type of treatment is non-invasive and therefore, a priori, it can be used in all types of patients. Main objective: To evaluate the efficacy of low-dose lung irradiation as an adjunctive treatment in interstitial pneumonia in patients with COVID-19 by improving the PAFI O2 by 20% measured 48h after treatment with respect to the pre baseline measurement. -irradiation.
Description: To evaluate the efficacy of low-dose pulmonary irradiation as an adjunctive treatment in interstitial pneumonia in patients with COVID-19 by improving the PAFI O2 by 20% measured 48h after treatment with respect to baseline pre-irradiation measurement. . In cases of impossibility the SaFiO2 will be determined
Measure: Efficacy of low-dose pulmonary irradiation assessed by change in PAFI O2 by 20% Time: Day 2 after interventional radiotherapyDescription: Lung toxicity measured according to CTCAEv5
Measure: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 Time: Day 30 and day 90 after interventional radiotherapyDescription: Chest CT
Measure: Change of the radiological image Time: Days 7 and day 30 after interventional radiotherapyDescription: Death of any cause
Measure: Overall mortality Time: Day 15 and Day 30 after interventional radiotherapyDescription: Interleukins IL-6, IL-10, IL-1, IL-2, IL-8 (pg/ml)
Measure: Measure of pro-inflammatory interleukins Time: Days 1, day 4 and day 7 after interventional radiotherapyDescription: TGF-β (ng/ml)
Measure: Measure of trasforming growth factor (TGF-b) Time: Days 1, day 4 and day 7 after interventional radiotherapyDescription: TNF-α (pg/ml)
Measure: Measure of tumor necrosis factor alpha (TNF-a) Time: Days 1, day 4 and day 7 after interventional radiotherapyDescription: Overexpression of L-, E-, and P-selectin
Measure: Determining overexpression of pro-inflammatory selectin Time: Days 1, day 4 and day 7 after interventional radiotherapyDescription: Overexpression of ICAM-1, VCAM
Measure: Determining cell adhesion molecules (CAMs) Time: Days 1, day 4 and day 7 after interventional radiotherapyDescription: PON-1(paraoxonase and arylesterase activity) (IU/ml)
Measure: Measure of marker of oxidative stress PON-1 Time: Days 1, day 4 and day 7 after interventional radiotherapyRECOVERY is a randomised trial investigating whether treatment with either Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin, Convalescent plasma, Synthetic neutralizing antibodies or Tocilizumab prevents death in patients with COVID-19.
Description: For each pairwise comparison with the 'no additional treatment' arm, the primary objective is to provide reliable estimates of the effect of study treatments on all-cause mortality.
Measure: All-cause mortality Time: Within 28 days after randomisationDescription: To assess the effects of study treatment on number of days stay in hospital
Measure: Duration of hospital stay Time: Within 28 days and up to 6 months after the main randomisationDescription: Among patients not on invasive mechanical ventilation at baseline, the number of patients with a composite endpoint of death or need for invasive mechanical ventilation or ECMO.
Measure: Composite endpoint of death or need for mechanical ventilation or ECMO Time: Within 28 days and up to 6 months after the main randomisationDescription: To assess the effects of study treatment on number of patients who needed ventilation and the number of days it was required
Measure: Need for (and duration of) ventilation Time: Within 28 days and up to 6 months after the main randomisationDescription: To assess the effects of study treatment on number of patients who needed renal replacement therapy
Measure: Need for renal replacement Time: Within 28 days and up to 6 months after the main randomisationDescription: To assess the effects of study treatment on number of patients who develop new major cardiac arrythmias
Measure: Development of new major cardiac arrythmias Time: Within 28 days and up to 6 months after the main randomisationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports